These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 16213697)

  • 1. Modification of eicosanoid profile in human blood treated by dual COX/LOX inhibitors.
    Pommery J; Pommery N; Hénichart JP
    Prostaglandins Leukot Essent Fatty Acids; 2005 Dec; 73(6):411-7. PubMed ID: 16213697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib.
    Li N; Sood S; Wang S; Fang M; Wang P; Sun Z; Yang CS; Chen X
    Clin Cancer Res; 2005 Mar; 11(5):2089-96. PubMed ID: 15756036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) selectivity of COX inhibitors.
    Sud'ina GF; Pushkareva MA; Shephard P; Klein T
    Prostaglandins Leukot Essent Fatty Acids; 2008 Feb; 78(2):99-108. PubMed ID: 18280718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eicosanoid metabolism in squamous cell carcinoma cell lines derived from primary and metastatic head and neck cancer and its modulation by celecoxib.
    Schroeder CP; Yang P; Newman RA; Lotan R
    Cancer Biol Ther; 2004 Sep; 3(9):847-52. PubMed ID: 15254428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and biological evaluation of a novel class of rofecoxib analogues as dual inhibitors of cyclooxygenases (COXs) and lipoxygenases (LOXs).
    Chen QH; Rao PN; Knaus EE
    Bioorg Med Chem; 2006 Dec; 14(23):7898-909. PubMed ID: 16904331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamic eicosanoid responses upon different inhibitor and combination treatments on the arachidonic acid metabolic network.
    He C; Wu Y; Lai Y; Cai Z; Liu Y; Lai L
    Mol Biosyst; 2012 Apr; 8(5):1585-94. PubMed ID: 22446875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous inhibition of COX-2 and 5-LOX activities augments growth arrest and death of premalignant and malignant human lung cell lines.
    Schroeder CP; Yang P; Newman RA; Lotan R
    J Exp Ther Oncol; 2007; 6(3):183-92. PubMed ID: 17552358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis of celecoxib analogs that possess a N-hydroxypyrid-2(1H)one 5-lipoxygenase pharmacophore: biological evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity.
    Chowdhury MA; Abdellatif KR; Dong Y; Das D; Suresh MR; Knaus EE
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6138-41. PubMed ID: 18945614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent development in the field of dual COX / 5-LOX inhibitors.
    Julémont F; Dogné JM; Pirotte B; de Leval X
    Mini Rev Med Chem; 2004 Aug; 4(6):633-8. PubMed ID: 15279597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases.
    Attiga FA; Fernandez PM; Weeraratna AT; Manyak MJ; Patierno SR
    Cancer Res; 2000 Aug; 60(16):4629-37. PubMed ID: 10969817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A rat air pouch model for evaluating the efficacy and selectivity of 5-lipoxygenase inhibitors.
    Zweifel BS; Hardy MM; Anderson GD; Dufield DR; Pufahl RA; Masferrer JL
    Eur J Pharmacol; 2008 Apr; 584(1):166-74. PubMed ID: 18295198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis of celecoxib analogues possessing a N-difluoromethyl-1,2-dihydropyrid-2-one 5-lipoxygenase pharmacophore: biological evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity.
    Chowdhury MA; Abdellatif KR; Dong Y; Das D; Suresh MR; Knaus EE
    J Med Chem; 2009 Mar; 52(6):1525-9. PubMed ID: 19296694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ER-34122, a novel dual 5-lipoxygenase/cyclooxygenase inhibitor with potent anti-inflammatory activity in an arachidonic acid-induced ear inflammation model.
    Horizoe T; Nagakura N; Chiba K; Shirota H; Shinoda M; Kobayashi N; Numata H; Okamoto Y; Kobayashi S
    Inflamm Res; 1998 Oct; 47(10):375-83. PubMed ID: 9831321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of pulmonary leukotriene B4 production by cyclooxygenase-2 inhibitors and lipopolysaccharide.
    Mao JT; Tsu IH; Dubinett SM; Adams B; Sarafian T; Baratelli F; Roth MD; Serio KJ
    Clin Cancer Res; 2004 Oct; 10(20):6872-8. PubMed ID: 15501964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eicosanoid Diversity of Stony Corals.
    Lõhelaid H; Samel N
    Mar Drugs; 2018 Jan; 16(1):. PubMed ID: 29301345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors.
    Hong SH; Avis I; Vos MD; Martínez A; Treston AM; Mulshine JL
    Cancer Res; 1999 May; 59(9):2223-8. PubMed ID: 10232612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of selective COX-2 and 5-LOX inhibition on prostaglandin and leukotriene synthesis in ductal pancreatic cancer in Syrian hamster.
    Gregor JI; Kilian M; Heukamp I; Kiewert C; Kristiansen G; Schimke I; Walz MK; Jacobi CA; Wenger FA
    Prostaglandins Leukot Essent Fatty Acids; 2005 Aug; 73(2):89-97. PubMed ID: 15964750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploration of binding site pattern in arachidonic acid metabolizing enzymes, Cyclooxygenases and Lipoxygenases.
    Reddy KK; Vidya Rajan VK; Gupta A; Aparoy P; Reddanna P
    BMC Res Notes; 2015 Apr; 8():152. PubMed ID: 25886468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of arachidonic-acid-metabolizing enzymes in adult Schistisoma mansoni.
    Abdel Baset H; O'Neill GP; Ford-Hutchinson AW
    Mol Biochem Parasitol; 1995 Jul; 73(1-2):31-41. PubMed ID: 8577345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of zileuton and celecoxib on urinary LTE4 and PGE-M levels in smokers.
    Mohebati A; Milne GL; Zhou XK; Duffield-Lillico AJ; Boyle JO; Knutson A; Bosworth BP; Kingsley PJ; Marnett LJ; Brown PH; Akpa EG; Szabo E; Dannenberg AJ
    Cancer Prev Res (Phila); 2013 Jul; 6(7):646-55. PubMed ID: 23682075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.